Oct 17 (Reuters) - EMA's CHMP:
EMA'S CHMP: ADOPTED POSITIVE OPINION FOR WAYRILZ FOR TREATMENT OF IMMUNE THROMBOCYTOPENIA IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS
EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR BRINSUPRI
EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR REZUROCK FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
EMA'S CHMP: WITHDRAWS INITIAL MARKETING APPLICATION FOR HYDROCORTISONE AGUETTANT
EMA'S CHMP: ADOPTED NEW SUBCUTANEOUS ROUTE OF ADMINISTRATION FOR SAPHNELO, AN ADD-ON TREATMENT IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
EMA'S CHMP: CONFIRMED ITS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE
EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR BREYANZI
EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR TREMFYA
EMA'S CHMP: CONFIRMS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE AS NEW ACTIVE SUBSTANCE
EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR PAXLOVID
((Reuters.Briefs@thomsonreuters.com;))